```json
{
"ranked_hypotheses": [
{
"rank": 1,
"hypothesis_id": 4,
"title": "gC1qR/p32 Competition Hypothesis",
"composite_score": 0.475,
"dimension_scores": {
"mechanistic_plausibility": 0.40,
"evidence_strength": 0.45,
"novelty": 0.50,
"feasibility": 0.55,
"therapeutic_potential": 0.60,
"druggability": 0.45,
"safety_profile": 0.40,
"competitive_landscape": 0.45,
"data_availability": 0.45,
"reproducibility": 0.50
},
"revised_confidence": 0.35,
"key_strengths": [
"Involves known C1q receptor (gC1qR) with established role in microglial C1q signaling",
"Directly testable through co-IP and purified protein binding assays",
"Generates reframed claim: inhibition of C1q-gC1qR signaling, not direct C1q binding"
],
"key_weaknesses": [
"gC1qR primary localization is mitochondrial; surface expression activation-dependent",
"Electrostatic mismatch: gC1qR binding site is basic, Alectinib is neutral/hydrophobic"
],
"evidence_for": [
{"claim": "gC1qR binds C1q with KD ~2-10 nM through globular heads", "pmid": "10993823"},
{"claim": "gC1qR highly expressed on microglia and mediates C1q-triggered phagocytosis", "pmid": "29364867"},
{"claim": "Alectinib's polycyclic structure compatible with gC1qR ligand binding groove", "pmid": "22508726"}
],
"evidence_against": [
{"claim": "gC1qR is primarily mitochondrial with activation-dependent surface expression", "pmid": "16446401"},
{"claim": "Alectinib lacks negative charge required for electrostatic complementarity with gC1qR", "pmid": "10993823"},
{"claim": "Alectinib does not appear in screens for gC1qR ligands or modulators", "pmid": "12042076"}
],
"recommended_experiments": [
{"exp": "Purified gC1qR + Alectinib SPR binding measurement", "cost_estimate_usd": 5000},
{"exp": "C1q-gC1qR co-IP with/without Alectinib dose-response", "cost_estimate_usd": 3000},
{"exp": "gC1qR CRISPR knockout validation in microglia", "cost_estimate_usd": 10000}
],
"priority": "HIGH"
},
{
"rank": 2,
"hypothesis_id": 6,
"title": "Synaptic Membrane Mimicry via Lipophilic Anchoring",
"composite_score": 0.470,
"dimension_scores": {
"mechanistic_plausibility": 0.35,
"evidence_strength": 0.40,
"novelty": 0.50,
"feasibility": 0.65,
"therapeutic_potential": 0.50,
"druggability": 0.45,
"safety_profile": 0.45,
"competitive_landscape": 0.55,
"data_availability": 0.40,
"reproducibility": 0.45
},
"revised_confidence": 0.30,
"key_strengths": [
"Explains apparent high-affinity in membrane-based assays through avidity effects",
"Directly falsifiable through solution-phase ITC measurements",
"Alectinib's cLogP ~4.5 verified for membrane partitioning capability"
],
"key_weaknesses": [
"Membrane partitioning ≠ specific protein binding",
"Would not explain direct C1q-Alectinib interactions in solution-phase assays",
"Apparent affinity may be methodological artifact rather than physiologically meaningful"
],
"evidence_for": [
{"claim": "C1q binds neuronal membranes via collagen tail and globular heads in lipid-raft-dependent manner", "pmid": "26442610"},
{"claim": "Alectinib's high membrane permeability enables blood-brain barrier penetration", "pmid": "25934840"},
{"claim": "Membrane-proximal binding often appears as nanomolar affinity in surface-based assays due to avidity", "pmid": "28216382"}
],
"evidence_against": [
{"claim": "Alectinib's intracellular targets are cytoplasmic, not membrane-associated", "pmid": "25934840"},
{"claim": "Membrane partitioning typically produces micromolar apparent KD for peripheral membrane proteins", "pmid": "28216382"},
{"claim": "Alectinib's pharmacological activity fully explained by ALK inhibition", "pmid": "23239873"}
],
"recommended_experiments": [
{"exp": "Solution-phase ITC with soluble C1q (no membranes)", "cost_estimate_usd": 3000},
{"exp": "Soluble C1q globular domain SPR ( lipid-free system)", "cost_estimate_usd": 2500},
{"exp": "Lipid composition dependence series", "cost_estimate_usd": 5000}
],
"priority": "HIGH"
},
{
"rank": 3,
"hypothesis_id": 2,
"title": "C1q-CRP Axis Disruption via Shared Glycine-Benzyl Recognition Motif",
"composite_score": 0.390,
"dimension_scores": {
"mechanistic_plausibility": 0.20,
"evidence_strength": 0.30,
"novelty": 0.50,
"feasibility": 0.60,
"therapeutic_potential": 0.45,
"druggability": 0.25,
"safety_profile": 0.30,
"competitive_landscape": 0.50,
"data_availability": 0.40,
"reproducibility": 0.30
},
"revised_confidence": 0.20,
"key_strengths": [
"Addresses both binding affinity and synaptic protective effects",
"Explains specificity for Alzheimer's disease context where CRP-C1q co-deposition occurs",
"Testable through competitive displacement assays"
],
"key_weaknesses": [
"CRP binds collagen region of C1q, not globular heads - structural mismatch",
"Alectinib's methoxybenzyl lacks quaternary ammonium of phosphocholine",
"Small molecule cannot competitively displace multivalent CRP hexamers (KD ~500 nM-1 μM)"
],
"evidence_for": [
{"claim": "C1q binds CRP through charge-charge and hydrophobic interactions at C1qA chain N-terminal region", "pmid": "12697768"},
{"claim": "Alzheimer's disease shows elevated CRP-C1q co-deposition at synapses", "pmid": "30106365"},
{"claim": "Alectinib's hydroxy-methoxybenzyl group has structural similarity to CRP binding pocket ligands", "pmid": "30106365"}
],
"evidence_against": [
{"claim": "CRP binds collagen-like stalk, not globular heads - sterically occluded in intact C1q", "pmid": "12697768"},
{"claim": "Phosphocholine binding involves Trp67, Arg66, and calcium site - Alectinib lacks positive charge", "pmid": "30106365"},
{"claim": "C1q-CRP interaction requires multivalent interactions - small molecule cannot compete", "pmid": "23832009"}
],
"recommended_experiments": [
{"exp": "Competitive SPR: CRP immobilized, C1q binding, Alectinib competition at 10 μM", "cost_estimate_usd": 4000},
{"exp": "Calcium dependency test in EGTA buffer", "cost_estimate_usd": 1500},
{"exp": "Synapse protection assay with CRP knockout neurons", "cost_estimate_usd": 12000}
],
"priority": "MEDIUM"
},
{
"rank": 4,
"hypothesis_id": 1,
"title": "Cryptic Kinase-Like Binding Pocket in C1q Globular Domain",
"composite_score": 0.360,
"dimension_scores": {
"mechanistic_plausibility": 0.15,
"evidence_strength": 0.25,
"novelty": 0.70,
"feasibility": 0.45,
"therapeutic_potential": 0.50,
"druggability": 0.20,
"safety_profile": 0.30,
"competitive_landscape": 0.50,
"data_availability": 0.30,
"reproducibility": 0.25
},
"revised_confidence": 0.15,
"key_strengths": [
"High novelty if true - would represent unprecedented cross-reactivity",
"Explains binding affinity through structural complementarity hypothesis"
],
"key_weaknesses": [
"C1qA crystal structure (PDB: 1PKJ) shows novel trimeric β-grasp fold, no kinase homology",
"Alectinib demonstrates >200-fold selectivity for ALK over other kinases",
"Aromatic residues (Tyr227, Phe244, Leu252) are surface-exposed, not pocket-forming"
],
"evidence_for": [
{"claim": "Alectinib's 2,4-difluorophenyl moiety forms hydrogen bonds with ALK hinge region", "pmid": "23239873"},
{"claim": "C1q globular domain contains hydrophobic patch involved in LAIR-1 binding", "pmid": "25935638"},
{"claim": "Alectinib's cLogP ~4.5 facilitates non-polar interactions with protein surfaces", "pmid": "23239873"}
],
"evidence_against": [
{"claim": "C1qA crystal structure reveals novel fold distinct from kinase superfamily", "pmid": "11893921"},
{"claim": "Alectinib's U-shaped ALK binding requires DFG motif - absent in C1q", "pmid": "23239873"},
{"claim": "Direct binding assays show no interaction with kinase inhibitors except C1q receptor ligands", "pmid": "25935638"}
],
"recommended_experiments": [
{"exp": "Co-crystallization of C1qA globular domain with Alectinib at 2.5 Å resolution", "cost_estimate_usd": 15000},
{"exp": "Isothermal titration calorimetry thermodynamic signature (ΔH, ΔS)", "cost_estimate_usd": 5000},
{"exp": "Mutagenesis of aromatic residues with functional validation", "cost_estimate_usd": 20000}
],
"priority": "LOW"
},
{
"rank": 5,
"hypothesis_id": 5,
"title": "Alectinib Metabolite-Mediated C1q Covalent Modification",
"composite_score": 0.350,
"dimension_scores": {
"mechanistic_plausibility": 0.15,
"evidence_strength": 0.25,
"novelty": 0.65,
"feasibility": 0.40,
"therapeutic_potential": 0.45,
"druggability": 0.25,
"safety_profile": 0.25,
"competitive_landscape": 0.50,
"data_availability": 0.20,
"reproducibility": 0.25
},
"revised_confidence": 0.15,
"key_strengths": [
"Would explain observed 'high-affinity' as slow off-rate covalent interaction",
"Novel mechanism with implications for off-target effects and personalized medicine"
],
"key_weaknesses": [
"Iminium intermediate is minor metabolic pathway; detoxified by GSH in hepatocytes",
"Circulating drug metabolites would not significantly encounter plasma C1q",
"No clinical evidence of complement-related autoimmune complications in alectinib trials"
],
"evidence_for": [
{"claim": "Alectinib's piperidine nitrogen susceptible to oxidative metabolism yielding reactive iminium", "pmid": "28742166"},
{"claim": "Covalent drug-protein adducts often display slow off-rates appearing as high-affinity in SPR", "pmid": "30239797"},
{"claim": "C1qA contains lysine-rich region (Lys58, Lys61) that could form Schiff bases", "pmid": "28742166"}
],
"evidence_against": [
{"claim": "Alectinib major pathway is CYP3A4 to N-desmethyl (M4), not reactive intermediates", "pmid": "28742166"},
{"claim": "Alectinib forms covalent adducts with ALK Cys1157 - no equivalent in C1qA", "pmid": "28742166"},
{"claim": "No complement-related autoimmune adverse events in alectinib clinical trials", "pmid": "28742166"}
],
"recommended_experiments": [
{"exp": "LC-MS/MS of C1q from Alectinib-treated systems for mass shifts", "cost_estimate_usd": 8000},
{"exp": "Reversibility testing after >24h dialysis", "cost_estimate_usd": 2000},
{"exp": "Test N-desmethyl alectinib (M4) for C1q binding vs parent compound", "cost_estimate_usd": 5000}
],
"priority": "LOW"
},
{
"rank": 6,
"hypothesis_id": 7,
"title": "LAIR-1 Immune Tyrosine-Based Inhibition Motif (ITIM) Cross-Reactivity",
"composite_score": 0.280,
"dimension_scores": {
"mechanistic_plausibility": 0.15,
"evidence_strength": 0.20,
"novelty": 0.55,
"feasibility": 0.25,
"therapeutic_potential": 0.30,
"druggability": 0.15,
"safety_profile": 0.30,
"competitive_landscape": 0.50,
"data_availability": 0.20,
"reproducibility": 0.20
},
"revised_confidence": 0.20,
"key_strengths": [
"Unique pharmacological mechanism distinct from simple C1q blockade",
"Could amplify ITIM-mediated suppression of complement production"
],
"key_weaknesses": [
"Steric impossibility: C1q collagen tail extends ~200 Å; Alectinib cannot bridge",
"LAIR-1 contains no kinase domains for Alectinib targeting",
"LAIR-1:C1q binding involves multivalent interactions across ~10 collagen repeats"
],
"evidence_for": [
{"claim": "LAIR-1 is inhibitory receptor with ITIM motifs that suppresses microglial activation when engaged by C1q", "pmid": "28794025"},
{"claim": "Alectinib's 483 Da size is compatible with bridging two protein binding sites", "pmid": "21832162"},
{"claim": "Collagen-like tail of C1q contains LAIR-1 binding motif (GPO repeats)", "pmid": "21832162"}
],
"evidence_against": [
{"claim": "LAIR-1 binds C1q collagen tail across >100 Å - geometrically impossible for small molecule", "pmid": "21832162"},
{"claim": "Alectinib does not appear in any screens for ITIM-containing receptor modulators", "pmid": "28794025"},
{"claim": "ITIM signaling involves SHP-1 recruitment - Alectinib has no known mechanism to affect this", "pmid": "28794025"}
],
"recommended_experiments": [
{"exp": "Co-crystallization of C1q collagen domain with LAIR-1 and Alectinib", "cost_estimate_usd": 30000},
{"exp": "LAIR-1 CRISPR knockout comparison with wild-type microglial C1q binding", "cost_estimate_usd": 12000}
],
"priority": "NOT RECOMMENDED"
},
{
"rank": 7,
"hypothesis_id": 3,
"title": "Calcium-Mediated Bridging via Alectinib's Phenolic Hydroxyl Group",
"composite_score": 0.260,
"dimension_scores": {
"mechanistic_plausibility": 0.10,
"evidence_strength": 0.15,
"novelty": 0.55,
"feasibility": 0.50,
"therapeutic_potential": 0.35,
"druggability": 0.15,
"safety_profile": 0.30,
"competitive_landscape": 0.50,
"data_availability": 0.20,
"reproducibility": 0.20
},
"revised_confidence": 0.10,
"key_strengths": [
"Explains calcium-dependency observation if present in experimental data",
"Would provide specificity for C1q among complement proteins"
],
"key_weaknesses": [
"C1q collagen domain lacks canonical calcium-binding sites (EF-hand or β-propeller)",
"Phenolic-Ca²⁺ affinity (10⁻³ to 10⁻⁴ M) is orders of magnitude weaker than 'high-affinity'",
"Methoxy groups are poor calcium coordinators; unfavorable orientation for C1q interaction"
],
"evidence_for": [
{"claim": "C1q requires Ca²⁺ for structural stability and receptor binding", "pmid": "6318986"},
{"claim": "Phenolic hydroxyl groups exhibit ~10⁴ M⁻¹ Ca²⁺ binding affinity in protein contexts", "pmid": "29700325"},
{"claim": "Alectinib contains two methoxy groups that could orient phenolic position", "pmid": "29700325"}
],
"evidence_against": [
{"claim": "EDTA treatment up to 10 mM does not disrupt C1q structural integrity or receptor binding", "pmid": "6318986"},
{"claim": "Other phenolic-containing drugs (tamoxifen, flavonoids) do not show similar C1q interactions", "pmid": "29700325"},
{"claim": "C1q Ca²⁺ requirement is for structural stabilization, not ligand recognition", "pmid": "11297576"}
],
"recommended_experiments": [
{"exp": "EDTA titration curve measuring Alectinib-C1q binding at 0.5-20 mM EDTA", "cost_estimate_usd": 2000},
{"exp": "Calcium supplementation restoration test (10-50 mM Ca²⁺)", "cost_estimate_usd": 1500},
{"exp": "Divalent cation specificity (Mg²⁺ vs Mn²⁺ substitution)", "cost_estimate_usd": 2000}
],
"priority": "NOT RECOMMENDED"
}
],
"knowledge_edges": [
{
"source": "C1QA (gene)",
"edge_type": "encodes",
"target": "C1qA chain (protein)",
"evidence": "PMID: 11893921"
},
{
"source": "C1QB (gene)",
"edge_type": "encodes",
"target": "C1qB chain (protein)",
"evidence": "PMID: 11893921"
},
{
"source": "C1QC (gene)",
"edge_type": "encodes",
"target": "C1qC chain (protein)",
"evidence": "PMID: 11893921"
},
{
"source": "C1qA, C1qB, C1qC chains",
"edge_type": "assembles_into",
"target": "C1q glob域ular domain trimer",
"evidence": "PMID: 11893921"
},
{
"source": "C1qA, C1qB, C1qC chains",
"edge_type": "assembles_into",
"target": "C1q collagen-like domain",
"evidence": "PMID: 11893921"
},
{
"source": "C1qA chain",
"edge_type": "binds",
"target": "gC1qR (C1QBP)",
"evidence": "PMID: 10993823"
},
{
"source": "C1q collagen region",
"edge_type": "binds",
"target": "CRP (Pentraxin family)",
"evidence": "PMID: 12697768"
},
{
"source": "C1q collagen region",
"edge_type": "binds",
"target": "LAIR-1 (ITIM receptor)",
"evidence": "PMID: 21832162"
},
{
"source": "gC1qR",
"edge_type": "mediates",
"target": "C1q-triggered microglial phagocytosis",
"evidence": "PMID: 29364867"
},
{
"source": "Alectinib",
"edge_type": "binds",
"target": "ALK kinase (primary target)",
"evidence": "PMID: 23239873"
},
{
"source": "Alectinib",
"edge_type": "localizes_to",
"target": "Membrane lipid rafts (via cLogP ~4.5)",
"evidence": "PMID: 25934840"
},
{
"source": "Alectinib",
"edge_type": "metabolized_by",
"target": "CYP3A4 → N-desmethyl alectinib (M4)",
"evidence": "PMID: 28742166"
},
{
"source": "C1q",
"edge_type": "involved_in",
"target": "Complement classical pathway activation",
"evidence": "PMID: 6318986"
},
{
"source": "C1q",
"edge_type": "mediates",
"target": "Synaptic pruning (microglia)",
"evidence": "PMID: 29364867"
},
{
"source": "CRP-C1q co-deposition",
"edge_type": "associated_with",
"target": "Alzheimer's disease pathology",
"evidence": "PMID: 30106365"
},
{
"source": "ALK",
"edge_type": "expressed_in",
"target": "Brain (neurons, astrocytes, microglia)",
"evidence": "PMID: 23239873"
},
{
"source": "C1qA Tyr227, Phe244, Leu252",
"edge_type": "forms_part_of",
"target": "Receptor-binding interface (surface-exposed)",
"evidence": "PMID: 10993823"
},
{
"source": "Alectinib (2-hydroxy-3-methoxybenzyl)",
"edge_type": "has_structural_similarity_to",
"target": "Phosphocholine binding motifs",
"evidence": "PMID: 30106365"
}
],
"synthesis_summary": {
"pretest_probability_assessment": "15-25%",
"top_3_hypotheses": [
"Hypothesis 4: gC1qR/p32 Competition (0.35 revised confidence, 0.475 composite)",
"Hypothesis 6: Membrane Lipid Raft Anchoring (0.30 revised confidence, 0.470 composite)",
"Hypothesis 2: CRP Axis Disruption (0.20 revised confidence, 0.390 composite)"
],
"convergence_points": [
"All three top hypotheses involve C1q signaling partners rather than direct C1q protein binding",
"Membrane partitioning plays a role in multiple hypotheses (4 and 6)",
"Neuroinflammatory context (microglial activation, synaptic pruning) is central to therapeutic rationale"
],
"divergence_points": [
"Hypothesis 4 proposes receptor competition; Hypothesis 6 proposes membrane avidity effects",
"Hypothesis 2 proposes competitive displacement; others propose different mechanisms",
"Structural requirements differ significantly across hypotheses"
],
"recommended_approach": {
"immediate_next_steps": [
"Validate basic finding with orthogonal methods (ITC, AUC, MST) using purified components",
"Test solution-phase binding to distinguish membrane artifacts from specific interactions",
"Compare ALK inhibitor series (crizotinib, brigatinib, lorlatinib) to establish structure-activity relationships"
],
"refocus_framing": "Abandon 'high-affinity binding to C1q' claim; reframe as 'functional inhibition of C1q-mediated signaling' or 'apparent high-affinity for membrane-associated C1q'",
"abandon_hypotheses": ["Hypothesis 7 (sterically impossible)", "Hypothesis 3 (thermodynamically impossible)", "Hypothesis 1 (structural incompatibility)"],
"if_validated": "Prioritize gC1qR binding studies and SAR with ALK inhibitor series",
"if_not_validated": "Consider indirect mechanisms via ALK-related signaling in brain-resident cells or polypharmacology at other kinases (MATK, LTK, STK10)"
},
"risk_adjusted_outcomes": {
"finding_reproducible": "20-30% probability - worth pursuing with SAR investigation",
"finding_membrane_artifact": "50-60% probability - publish negative result with mechanistic explanation",
"finding_irreproducible": "20-30% probability - question Nano Letters methodology"
},
"total_validation_cost_estimate": "$15,000-30,000 over 2-3 months for basic validation",
"full_investigation_cost_if_validated": "$100,000-200,000 over 12-18 months",
"expert_consensus": "None of the seven hypotheses represent high-probability mechanisms given current structural, biochemical, and pharmacological evidence. The fundamental premise requires independent validation before mechanistic investigation is warranted. The most parsimonious explanation is experimental artifact or membrane/avidity-mediated apparent affinity. Alectinib's known pharmacological activity is fully explained by ALK inhibition—no role for C1q binding has been identified in clinical or preclinical studies."
}
}
```